The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | First-line ibrutinib and venetoclax in CLL
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses long-term follow-up data from a study assessing ibrutinib and venetoclax as first-line therapy in patients with chronic lymphocytic leukemia (CLL). 120 patients received the combination and after a 24 month follow-up, a majority of patients achieved a minimal residual disease (MRD) negative status. In patients who remained MRD positive, additional ibrutinib and venetoclax resulted successfully resulted in MRD negativity after another 12 month follow-up. The results are consistent with the findings from the Phase II CAPTIVATE trial (NCT02910583), highlighting ibrutinib and venetoclax as a promising therapy for CLL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
